TY - JOUR
T1 - Characteristics and Treatment Patterns of Long-surviving Patients With Multiple Myeloma
T2 - Over 13 Years of Follow-up in the ConnectⓇ MM Registry
AU - Terebelo, Howard R.
AU - Omel, James
AU - Wagner, Lynne I.
AU - Hardin, James W.
AU - Rifkin, Robert M.
AU - Ailawadhi, Sikander
AU - Durie, Brian G.M.
AU - Narang, Mohit
AU - Toomey, Kathleen
AU - Gasparetto, Cristina J.
AU - Joshi, Prashant
AU - Yu, Edward
AU - Flick, E. Dawn
AU - Jou, Ying Ming
AU - Lee, Hans C.
AU - Abonour, Rafat
AU - Jagannath, Sundar
N1 - Publisher Copyright:
© 2024 The Authors
PY - 2025/1
Y1 - 2025/1
N2 - Background: Over the last 15 years, improvements in patient management and treatments have been associated with longer survival in patients with multiple myeloma (MM). The Connect MM Registry is a long-running, US, multicenter, prospective observational cohort study of patients with newly diagnosed MM (NDMM). We assessed the demographics, clinical characteristics, and treatment patterns of long-term survivors (LTS) enrolled in this registry. Methods: Adults with NDMM (n = 3,011) were enrolled from 250 community, academic, and government sites across the US from 2009-2016. Baseline characteristics, treatment patterns, quality of life (QoL), and overall survival (OS) were examined among LTS, defined as patients with follow-up of ≥ 8 years after enrollment. Results: As of February 7, 2023, 518 patients were LTS and 2,493 were non-LTS. LTS were generally younger and had better performance status at enrollment compared with non-LTS. Most (65%) LTS received stem cell transplants and few (2%) experienced disease progression within 6 months of starting first line of therapy. At data cutoff, 63% of LTS were still on treatment at their most recent visit. QoL scores and QoL questionnaire completion rates were consistently higher among LTS than non-LTS. The estimated 8-year OS rate of all patients enrolled in the registry was 40%, comparable to an observed 8-year survival of 39% from the Surveillance, Epidemiology, and End Results (SEER) database. Conclusion: This analysis provides insights on long-surviving patients with MM using real-world data and therefore presents generalizability beyond data obtained in long-term follow-up of clinical trials, underscoring the need for longitudinal follow-up through registries.
AB - Background: Over the last 15 years, improvements in patient management and treatments have been associated with longer survival in patients with multiple myeloma (MM). The Connect MM Registry is a long-running, US, multicenter, prospective observational cohort study of patients with newly diagnosed MM (NDMM). We assessed the demographics, clinical characteristics, and treatment patterns of long-term survivors (LTS) enrolled in this registry. Methods: Adults with NDMM (n = 3,011) were enrolled from 250 community, academic, and government sites across the US from 2009-2016. Baseline characteristics, treatment patterns, quality of life (QoL), and overall survival (OS) were examined among LTS, defined as patients with follow-up of ≥ 8 years after enrollment. Results: As of February 7, 2023, 518 patients were LTS and 2,493 were non-LTS. LTS were generally younger and had better performance status at enrollment compared with non-LTS. Most (65%) LTS received stem cell transplants and few (2%) experienced disease progression within 6 months of starting first line of therapy. At data cutoff, 63% of LTS were still on treatment at their most recent visit. QoL scores and QoL questionnaire completion rates were consistently higher among LTS than non-LTS. The estimated 8-year OS rate of all patients enrolled in the registry was 40%, comparable to an observed 8-year survival of 39% from the Surveillance, Epidemiology, and End Results (SEER) database. Conclusion: This analysis provides insights on long-surviving patients with MM using real-world data and therefore presents generalizability beyond data obtained in long-term follow-up of clinical trials, underscoring the need for longitudinal follow-up through registries.
KW - Newly diagnosed multiple myeloma
KW - Registry
KW - Stem cell transplant
KW - Survival
KW - Triplet therapy
UR - http://www.scopus.com/inward/record.url?scp=85210294923&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2024.11.001
DO - 10.1016/j.clml.2024.11.001
M3 - Article
AN - SCOPUS:85210294923
SN - 2152-2650
VL - 25
SP - 58
EP - 66
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 1
ER -